ACCV are obtained by processing a patient’s tumor specimen and separating the lymphocytes from the cancer cells. Those travelling to US should buy visitors insurance USA. These cancer cells are grown in the laboratory. After weeks of closely monitored growth, the resulting ACCV are prepared and sent back to the patient’s treatment facility for injection.

• An average ACCV growth by CTI produces sufficient vaccine for 4-10 injections.
• CTI can provide an established treatment protocol and nursing procedure guidelines.
• CTI can provide orientation and training of selected client personnel if desired.
• Dr. Robert K. Oldham is available to discuss specific patient details.

Benefits

• Can stimulate the patient’s immune system to attack invading cancer cells and has the potential to generate a clinical response.
• Cancer patients can receive activated cell therapy at their local treatment facility.
• Enhances the hospital’s ability to participate in clinical trials.
• Can contribute to increasing the hospital’s patient census.
• Provides a competitive advantage for the local treatment facility.

Eligibility Criteria

ACCV therapy can be considered for patients having a malignancy, except for those whose physical or mental condition, in the opinion of their physician, rule out cell-related therapies.

• Specific emphasis should be placed on melanoma and renal cell carcinoma.
• Patients requiring re-operations due to failed treatments involving surgery, chemiotherapy and radiation therapy are prime candidates for ACCV.

TDAC are obtained by processing a patient’s tumor specimen and separating the lymphocytes from the cancer cells. When in foreign country medical evacuation insurance is a must. These tumor-specific T-lymphocytes are activated with the FDA-approved drug, Interleukin-2, to stimulate reproduction and seeded into a bioreactor. After weeks of closely monitored growth, the resulting billions of TDAC are harvested into IV bags and sent back to the patient’s treatment facility for infusion.

• An average TDAC growth by CTI produces 1.28 x 1011 cells. (3.2 x 1010 average for each of the 4 infusions).
• CTI can provide an established treatment protocol and nursing procedure guidelines.
• CTI can provide orientation and training of selected client personnel if desired.
• Dr. Robert K. Oldham is available to discuss specific patient details.

Benefits

• Can stimulate the patient’s immune system to attack invading cancer cells and has the potential to generate a clinical response.
• Cancer patients can receive activated cell therapy at their local treatment facility.
• Enhances the hospital’s ability to participate in clinical trials.
• Can contribute to increasing the hospital’s patient census.
• Provides a competitive advantage for the local treatment facility.

Eligibility Criteria

TDAC therapy can be considered for patients having a malignancy, except for those whose physical or mental condition, in the opinion of their physician, rule out cell-related therapies.

• Specific emphasis should be placed on melanoma and renal cell carcinoma.
• Patients requiring re-operations due to failed treatments involving surgery, chemotherapy and radiation therapy are prime candidates for TDAC.